A Pharmacokinetic/Pharmacodynamic Evaluation of ABF656 in Subjects With Chronic Hepatitis B, e Ag+, Infection.

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 20 Apr 2016

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Albinterferon alfa 2B (Primary) ; Peginterferon alfa-2a
Indications Hepatitis B
Focus Adverse reactions; Pharmacodynamics
Sponsors Novartis

Most Recent Events

23 Nov 2012 Company 'GlaxoSmithKline' added as reported by ClinicalTrials.gov.
05 Oct 2010 The status of this trial is uncertain because development of albinterferon alfa 2B has been discontinued, as reported by a Novartis media release.
01 Sep 2009 New trial record

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight